Archive for the ‘nature medicine retractions’ Category
Nearly six months after first expressing concern about the validity of a 2010 paper on multiple sclerosis, Nature Medicine has retracted the article for containing “erroneous” data — which in this case don’t seem to have existed, making them more fabricated than wrong.
The paper, “Crucial role of interleukin-7 in T helper type 17 survival and expansion in autoimmune disease,” came from a group led by Jingwu Zhang, who at the time ran GlaxoSmithKline’s Research and Development Center in Shanghai.
In what could be a significant blow to a major pharmaceutical company, Nature Medicine is reportedly set to retract a 2010 article by a group of researchers affiliated with a Chinese arm of the drug giant GlaxoSmithKline.
We’re not the first to report the news — you can read coverage of it on In the Pipeline and Pharmalot, for starters — which includes the revelation that Glaxo has fired Jingwu Zang, a co-author of the suspect paper and former senior vice president and head of research and development at the Shanghai facility: in other words, a big fish. (Big enough to have a profile in, well, Nature Reviews Drug Discovery.)
Pharmalot has quoted a Glaxo spokeswoman: Read the rest of this entry »
Corrections in PLoS One, Nature Medicine for Zhiguo Wang, and details about Montreal Heart Institute investigation
PLoS One and Nature Medicine have issued corrections for papers by Zhiguo Wang, the former Montreal Heart Institute researcher who resigned in September following an investigation into image manipulation in his lab.
In September, PLoS One told us that they were investigating the paper. Here’s the text of the correction for “Transcriptional and Post-Transcriptional Mechanisms for Oncogenic Overexpression of Ether À Go-Go K+ Channel:” Read the rest of this entry »
Nature Medicine paper by former Montreal Heart Institute researcher Zhiguo Wang unlikely to be retracted
We’ve been reporting on the case of Zhiguo Wang, the Montreal Heart Institute researcher who was dismissed earlier this month for scientific misconduct. In the announcement about Wang’s dismissal, the institute said it had requested the retraction of three papers other than the two that Wang had himself retracted earlier this summer, making a total of five.
We’ve been following up with journals that published Wang’s work, with the help of eagle-eyed Retraction Watch readers, and last week reported on the first of those three additional retractions, in the Journal of Cell Science. Late last week, we heard from Juan Carlos Lopez, the chief editor of Nature Medicine, which had published a paper by the group. Lopez had earlier said he was waiting for a Montreal Heart Institute report on their findings. He tells us it’s unlikely the Nature Medicine paper will be among those retracted: Read the rest of this entry »
The authors of a Nature Medicine study published online in September about the behavior of white blood cells in cystic fibrosis have retracted the paper, saying that further experiments suggested the original results were unreliable. According to the notice: Read the rest of this entry »
Nature Medicine has retracted a paper that Anil Potti’s co-author, Joseph Nevins, requested be withdrawn in November.
This is the second retraction of a paper by Potti, who resigned from his post at Duke in November in the midst of an investigation into scientific misconduct. The first retraction was in the Journal of Clinical Oncology.
It’s fair to say that we haven’t heard the last of Anil Potti, the Duke cancer researcher who resigned last month following revelations that he had faked some of his results. Duke is still investigating the situation, and has also asked the Institute of Medicine to conduct its own study into the case and its ramifications.
This week, we may find out whether Nature Medicine will retract a paper that Joseph Nevins, one of Potti’s co-authors, asked the journal to withdraw last month. We’re also keeping an eye on two other papers that have already been the subject of increased scrutiny: Read the rest of this entry »